Aspirin Trelamine

US Approved OTC

First marketed in 1899

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H21NO4
Molecular Weight	279.3315
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCN(CC)CCOC(=O)C1=CC=CC=C1OC(C)=O

InChI

InChIKey=GHIVDTCFLFLOBV-UHFFFAOYSA-N

InChI=1S/C15H21NO4/c1-4-16(5-2)10-11-19-15(18)13-8-6-7-9-14(13)20-12(3)17/h6-9H,4-5,10-11H2,1-3H3

HIDE SMILES / InChI

Molecular Formula	C15H21NO4
Molecular Weight	279.3315
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/011483s029lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/11723249

Aspirin is a nonsteroidal anti-inflammatory drug. Aspirin is unique in this class of drugs because it irreversibly inhibits both COX-1 and COX-2 activity by acetylating a serine residue (Ser529 and Ser516, respectively) positioned in the arachidonic acid-binding channel, thus inhibiting the synthesis of prostaglandins and reducing the inflammatory response. The drug is used either alone or in combination with other compounds for the treatment of pain, headache, as well as for reducing the risk of stroke and heart attacks in patients with brain ischemia and cardiovascular diseases.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Prostaglandin G/H synthase 1 30 Target ID: P23219\|\|\|Q5T7T7 Gene ID: 5742.0 Gene Symbol: PTGS1 Target Organism: Homo sapiens (Human) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/200671s000lbl.pdf	Inhibitor 8504		1.2 µM [IC50]
Prostaglandin G/H synthase 2 51 Target ID: P35354 Gene ID: 5743.0 Gene Symbol: PTGS2 Target Organism: Homo sapiens (Human) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/011483s029lbl.pdf	Inhibitor 8504		5.2 µM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Pain 619 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/011483s029lbl.pdf	Primary	Approved 8583	SYNALGOS-DC Approved Use SYNALGOS-DC is a combination of dihydrocodeine, an opioid agonist, aspirin, a nonsteroidal anti-inflammatory drug, and caffeine, a methylxanthine, and is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Launch Date 1958
Headache 47 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a00c6776-e9ef-411b-9396-915c3787559a	Primary	Approved 8583	FIORINAL Approved Use FIORINAL is indicated for the relief of the symptom complex of tension (or muscle contraction) headache. Evidence supporting the efficacy and safety of Fiorinal in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because butalbital is habit-forming and potentially abusable. Launch Date 1976
Myocardial infarction 125 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/200671s000lbl.pdf	Preventing	Approved 8583	DURLAZA Approved Use DURLAZA is a nonsteroidal anti-inflammatory drug indicated to reduce the risk of death and myocardial infarction (MI) in patients with chronic coronary artery disease, such as patients with a history of MI or unstable angina pectoris or with chronic stable angina and to reduce the risk of death and recurrent stroke in patients who have had an ischemic stroke or transient ischemic attack. Launch Date 2015
Stroke 144 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20884_AGGRENOX_prntlbl.pdf	Preventing	Approved 8583	AGGRENOX Approved Use AGGRENOX is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. Launch Date 1999

C_max

Value	Dose	Co-administered	Analyte	Population
54.25 mg/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:		ASPIRIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
4.84 mg/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:		ASPIRIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
10.31 mg × h/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:		ASPIRIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
5.12 mg × h/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:		ASPIRIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
0.322 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:		ASPIRIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.422 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:		ASPIRIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
68% REVIEW https://www.ncbi.nlm.nih.gov/pubmed/30115648			ASPIRIN plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inducer 1087	substrate 1193	substrate 1388 inducer 109

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OAT3 747	CYP1A2 1197 CYP2A6 626 CYP2B6 776 CYP2C8 810 CYP2C19 1119 CYP2E1 729 esterase 74 UGT1A1 479 UGT1A3 470 UGT1A6 343 UGT1A7 249 UGT1A8 323 UGT1A9 423 UGT1A10 331 UGT2B4 278 UGT2B7 456 P-gp 2052	CYP2C19 329 CYP1A2 832 CYP2E1 131 ABCA1 19 P-gp 301

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inducer 1966 Sources: https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1067/mcp.2003.14 Page: -	no
CYP2D6 2546	inducer 1966 Sources: https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1067/mcp.2003.14 Page: -	no
CYP2E1 1146	inducer 1966 Sources: https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1067/mcp.2003.14 Page: -	no
ABCA1 19	inducer 1966 Sources: https://www.karger.com/Article/Abstract/321727 Page: -	yes
CYP2C19 2141	inducer 1966 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	yes
CYP3A4 2633	inducer 1966 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	yes
OAT3 749	inhibitor 4027 Sources: https://dmd.aspetjournals.org/content/42/6/996.short Page: -	yes
P-gp 1932	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/11205285/ Page: -	yes

Drug as victim

Target	Modality	Activity	Metabolite
CYP1A2 1197	substrate 4014 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	no
CYP1A2 1197	substrate 4014 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	no	salicylic acid 18
CYP2A6 626	substrate 4014 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	no
CYP2B6 776	substrate 4014 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	no
CYP2B6 776	substrate 4014 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	no	salicylic acid 18
CYP2C19 1119	substrate 4014 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	no
CYP2C8 810	substrate 4014 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	no
CYP2C9 1193	substrate 4014 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	no
CYP2D6 1388	substrate 4014 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	no
CYP3A4 1946	substrate 4014 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	no
P-gp 2052	substrate 4014 Sources: https://www.tandfonline.com/doi/full/10.1080/00498254.2020.1757785 Page: -	no
UGT1A8 323	substrate 4014 Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: -	no	salicylic acid 18
UGT2B4 278	substrate 4014 Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: -	no	salicylic acid 18
UGT2B7 456	substrate 4014 Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: -	yes [Km 1242 uM]	salicylic acid 18
UGT1A3 470	substrate 4014 Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: -	yes [Km 2337 uM]	salicylic acid 18
UGT1A7 249	substrate 4014 Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: -	yes [Km 278.6 uM]	salicylic acid 18
UGT1A6 343	substrate 4014 Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: -	yes [Km 40.7 uM]	salicylic acid 18
UGT1A1 479	substrate 4014 Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: -	yes [Km 683.1 uM]	salicylic acid 18
UGT1A10 331	substrate 4014 Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: -	yes [Km 698.2 uM]	salicylic acid 18
UGT1A9 423	substrate 4014 Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: -	yes [Km 94.2 uM]	salicylic acid 18
CYP2A6 626	substrate 4014 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	yes	salicylic acid 18
CYP2C19 1119	substrate 4014 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	yes	salicylic acid 18
CYP2C8 810	substrate 4014 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	yes	salicylic acid 18
CYP2C9 1193	substrate 4014 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	yes	salicylic acid 18
CYP2D6 1388	substrate 4014 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	yes	salicylic acid 18
CYP2E1 729	substrate 4014 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	yes	salicylic acid 18
CYP3A4 1946	substrate 4014 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	yes	salicylic acid 18
esterase 74	substrate 4014 Sources: https://www.sciencedirect.com/science/article/pii/S0928098715001153 Page: -	yes

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B1-00059	http://www.3bsc.com/index/pro_info.php?id=20271
AA Blocks	AA00I8UA	http://www.aablocks.com/goods/Goods/detail?id=AA00I8UA
Aaron Chemicals	AR00I9M2	http://www.aaronchem.com/50-78-2
abcr GmbH	AB113303	http://www.abcr.com/shop/en/AB113303
AbMole Bioscience	M5426	http://www.abmole.com/products/aspirin.html
Acadechem	ACDS-070196	http://www.acadechemical.com/product/144895
Achemica	ACMC-209kpz	http://www.achemica.com/prodinfo/?id=128318
Achemo Scientific Limited	AC-24217	http://www.achemo.com/search/?Keyword=50-78-2
Achemtek	0104-001327	http://www.achemtek.com/50-78-2
Acros Organics	AC158180025	https://www.fishersci.com/shop/products/acetylsalicylic-acid-99-acros-organics/AC158180025
Acros Organics	AC158180500	https://www.fishersci.com/shop/products/acetylsalicylic-acid-99-acros-organics-1/AC158180500
Acros Organics	AC158185000	https://www.fishersci.com/shop/products/acetylsalicylic-acid-99-acros-organics-1/AC158185000
AK Scientific, Inc. (AKSCI)	H740	http://www.aksci.com/item_detail.php?cat=H740
Alfa Aesar	A12488	https://www.alfa.com/en/catalog/A12488/
Ambinter	Amb17757514	http://www.ambinter.com/reference/17757514
Angene	AGN-PC-0WACEM	http://www.angenechemical.com/productshow/AGN-PC-0WACEM.html
Anward	ANW-31125	http://www.anward.com/pro_result/20981
ApexBio Technology	A4013	http://www.apexbt.com/aspirin-acetylsalicylic-acid.html
Aurora Fine Chemicals LLC	A00.156.463	http://online.aurorafinechemicals.com/info?ID=A00.156.463
Aurora Fine Chemicals LLC	K00.801.915	http://online.aurorafinechemicals.com/info?ID=K00.801.915
Avantor Inc	TCA2262-25G	https://us.vwr.com/store/product/9983116/o-acetylsalicylic-acid-98-0-by-gc-titration-analysis
BioChemPartner	BCP21790	http://www.biochempartner.com/50-78-2-BCP21790
BioCrick	BCC2097	http://www.biocrick.com/Aspirin-Acetylsalicylic-acid-BCC2097.html
BOC Sciences	1173022-25-7	https://isotope.bocsci.com/product/acetylsalicylic-acid-13c-cas-1173022-25-7-343874.html
BOC Sciences	921943-73-9	https://www.bocsci.com/acetylsalicylic-acid-d3-cas-921943-73-9-item-466862.html
BOC Sciences	97781-16-3	https://www.bocsci.com/2-acetoxybenzoic-3-4-5-6-d4-acid-cas-97781-16-3-item-212339.html
Boerchem	BC221833	http://www.boerchem.com/?product_37473.html
Capot Chemical	20190	http://www.capotchem.com/en/20190.htm
Capot Chemical	PubChem20190	http://www.capotchem.com/en/20190.htm
Chem Scene	CS-2001	http://www.chemscene.com/50-78-2.html
ChemMol	49417180	http://www.chemmol.com/chemmol/49417180.html
ChemMol	99097732	http://www.chemmol.com/chemmol/99097732.html
Chemspace	CSSB00000210466	https://chem-space.com/CSSB00000210466
Clearsynth	CS-EG-00025	https://www.clearsynth.com/en/CSEG00025.html
Clearsynth	CS-ER-02340	https://www.clearsynth.com/en/CSER02340.html
Clearsynth	CS-T-01103	https://www.clearsynth.com/en/CST01103.html
Clearsynth	CS-T-47333	https://www.clearsynth.com/en/CST47333.html
DC Chemicals	DC8956	http://www.dcchemicals.com/product_show-Acetylsalicylic_acid.html
Debye Scientific	DS-017139	http://www.debyesci.com/cas_59096-14-9.html
Enamine	Z234893989	https://www.enaminestore.com/catalog/Z234893989
eNovation Chemicals	D408997	http://www.enovationchem.com/productDetails.asp?productID=D408997
Finetech	FT-0655181	http://www.finetechnology-ind.com/prod/detail/pub/50-78-2.html
Finetech	FT-0661360	http://www.finetechnology-ind.com/prod/detail/pub/97781-16-3.html
Glentham Life Sciences	GL0865	http://www.glentham.com/products/product/GL0865/
Hairui	HR138909	http://www.hairuichem.com/en/product/50-78-2.html
iChemical	EBD47326	http://www.ichemical.com/products/50-78-2.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
Lab Network	LN00223310	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00223310
LGC Standards	DRE-C10024000	https://www.lgcstandards.com/US/en/p/DRE-C10024000
LGC Standards	LGCAMP0133.00-11	https://www.lgcstandards.com/US/en/p/LGCAMP0133.00-11
LGC Standards	LGCFOR0133.00	https://www.lgcstandards.com/US/en/p/LGCFOR0133.00
LGC Standards	MM0133.00-0250	https://www.lgcstandards.com/US/en/p/MM0133.00-0250
Matrix Scientific	134531	https://www.matrixscientific.com/134531.html
mcule	MCULE-3199019536	https://mcule.com/MCULE-3199019536/
MedChem Express	HY-14654	https://www.medchemexpress.com/aspirin.html
MuseChem	A000653	https://www.musechem.com/product/A000653.html
Oakwood	101923	http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=130521&ExtHyperLink=1
Parchem	12326	http://www.parchem.com/chemical-supplier-distributor/Aspirin-USP-26-002326.aspx
Parchem	30461	http://www.parchem.com/chemical-supplier-distributor/Aspirin-USP-3080--020461.aspx
Parchem	30462	http://www.parchem.com/chemical-supplier-distributor/Aspirin-USP-2080B--020462.aspx
Selleck Chemicals	S3017	http://www.selleckchem.com/products/aspirin-acetylsalicylic-acid.html
Sigma-Aldrich	1044006_USP	https://www.sigmaaldrich.com/catalog/product/usp/1044006?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	239631_ALDRICH	https://www.sigmaaldrich.com/catalog/product/aldrich/239631?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	A0200000_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/a0200000?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	A2093_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/a2093?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	A3160_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/a3160?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech	S054539	http://www.sinfoobiotech.com/product/1057937
Smolecule	S519564	http://www.smolecule.com/products/s519564
Synthetic Heterocycles	AFA100669	http://www.synhet.com/products/AFA100669
TCI (Tokyo Chemical Industry)	A2262	http://www.tcichemicals.com/eshop/en/us/commodity/A2262/index.html
THE BioTek	bt-260267	https://www.thebiotek.com/product/inhibitors/bt-260267
Tocris	4092	https://www.tocris.com/products/aspirin_4092
Vitas-M Laboratory	BBL005469	http://www.request.vitasmlab.biz/index.php?option=com_search_stk&Itemid=22&stk=BBL005469&?utm_source=pubchem&utm_medium=p_search_link&utm_campaign=pubchem_search&utm_content=pubchem_slink
VladaChem	VL271248-100G	https://www.vladachem.com/product.php?products=50-78-2
Yuhao Chemical	RT12808	http://www.chemyuhao.com/50-78-2.html

PubMed

Title	Date	PubMed
Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review.	2001-02-10	11159655
Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation.	2001-02-10	11159653
Heterogenous nature of flow-mediated dilatation in human conduit arteries in vivo: relevance to endothelial dysfunction in hypercholesterolemia.	2001-02-02	11157665
Cardiac risk factors, medication, and recurrent clinical events after acute coronary disease; a prospective cohort study.	2001-02	11161949
Non-steroidal anti-inflammatory drugs and gastrointestinal damage-problems and solutions.	2001-02	11161072
A novel synthetic inhibitor of factor Xa decreases early reocclusion and improves 24-h patency after coronary fibrinolysis in dogs.	2001-02	11160645
The effects of diaspirin cross-linked hemoglobin on the tone of human saphenous vein.	2001-02	11159224
Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study.	2001-02	11158211
Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II).	2001-02	11157179
Use of aspirin, epistaxis, and untreated hypertension as risk factors for primary intracerebral hemorrhage in middle-aged and elderly people.	2001-02	11157173
Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery.	2001-01-23	11157686
Authors' reply on aspirin for primary prevention.	2001-01-20	11159585
Salicylate and cocaine: interactive toxicity during chicken mid-embryogenesis.	2001-01-15	11163537
Salicylates inhibit T cell adhesion on endothelium under nonstatic conditions: induction of L-selectin shedding by a tyrosine kinase-dependent mechanism.	2001-01-15	11145657
Drug Points: tachycardia associated with moxifloxacin.	2001-01-06	11141146
Pharmacological properties of a newly synthesized H(+)/K(+) ATPase inhibitor, 1-(2-methyl-4-methoxyphenyl)-4-.	2001-01-05	11137875
Blood donations and risk of coronary heart disease in men.	2001-01-02	11136685
Local delivery of enoxaparin to decrease restenosis after stenting: results of initial multicenter trial: Polish-American Local Lovenox NIR Assessment study (The POLONIA study).	2001-01-02	11136681
Low-grade exercise enhances platelet aggregability in patients with obstructive coronary disease independently of myocardial ischemia.	2001-01-01	11137827
Addition of hydrophilic and lipophilic compounds of biological relevance to the monoolein/water system. I. Phase behavior.	2001-01	11163344
Present treatment options for unstable angina and non-Q-wave myocardial infarction.	2001-01	11161130
Antithrombotic agents in coronary artery disease.	2001-01	11157652
Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves.	2001-01	11157651
Antithrombotic therapy in atrial fibrillation.	2001-01	11157649
Use of antithrombotic agents during pregnancy.	2001-01	11157646
Platelet-active drugs : the relationships among dose, effectiveness, and side effects.	2001-01	11157642
Gastric mucosal resistance to acute injury in experimental portal hypertension.	2001-01	11156591
Angioplasty increases coronary sinus F2-isoprostane formation: evidence for in vivo oxidative stress during PTCA.	2001-01	11153776
Multiple endothelial injury in epicardial coronary artery induces downstream microvascular spasm as well as remodeling partly via thromboxane A2.	2001-01	11153757
Lp(a) lipoprotein--an independent risk factor for coronary heart disease after menopause.	2001-01	11153187
The PlA polymorphism of glycoprotein IIIa functions as a modifier for the effect of estrogen on platelet aggregation.	2001-01	11151063
Prehospital management of rapid atrial fibrillation: recommendations for treatment protocols.	2001-01	11146008
Endogenous nitric oxide and prostaglandins synergistically counteract thromboembolism in arterioles but not in venules.	2001-01	11145949
Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis.	2001-01	11145946
Low-dose aspirin therapy and periodontal attachment loss in ex- and non-smokers.	2001-01	11142665
Selectivity of recombinant human leukotriene D(4), leukotriene B(4), and lipoxin A(4) receptors with aspirin-triggered 15-epi-LXA(4) and regulation of vascular and inflammatory responses.	2001-01	11141472
[Leukocytoclastic vasculitis associated with ticlopidine].	2001-01	11141463
Antithrombotic therapy in cardiac stent patients.	2001-01	11139803
Anticoagulation and heart failure.	2001-01	11139802
Is optimal antithrombotic therapy after myocardial infarction well defined?	2001-01	11139799
Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs.	2001-01	11138826
Diabetes mellitus with left transverse sinus thrombosis and right transverse sinus aplasia.	2001-01	11137180
Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo.	2001-01	11136483
Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans.	2001-01	11136272
Prevention of pre-eclampsia: status and perspectives 2000.	2001-01	11134820
Hemoglobin and methemoglobin concentrations after large-dose infusions of diaspirin cross-linked hemoglobin.	2001-01	11133598
Effect of acetylsalicylic acid on endogenous I kappa B kinase activity in lung epithelial cells.	2001-01	11133489
Novel platelet inhibitors.	2001	11160773
Human herpesvirus 8 K1-associated nuclear factor-kappa B-dependent promoter activity: role in Kaposi's sarcoma inflammation?	2001	11158202
Letter: Aspirin sensitivity: other drugs.	1975-02	1115460

Patents

Sample Use Guides

In Vivo Use Guide

Severe pain: Initiate treatment with two capsules (1 capsule contains 16 mg dihydrocodeine bitartrate, 356.4 mg aspirin, and 30 mg caffeine) orally every 4 hours as needed for pain. Headache: One or 2 capsules (1 capsule contains 50 mg butalbital, 325 mg aspirin and 40 mg caffeine) every 4 hours. Total daily dose should not exceed 6 capsules. Prevention of stoke and heart attacks: the recommended dose is one capsule of aspirin (162.5 mg) once daily. Take the capsules with a full glass of water at the same time each day. Prevention of stroke (in combination with dipyridamole): the recommended dose is one capsule (200 mg dipyridamole and 25 mg aspirin) given orally twice daily.

Route of Administration: Enteral

In Vitro Use Guide

Human platelet-rich plasma was incubated with various aspirin concentrations (10, 20, 50, 100, 200, 300, 400, 500 uM) at 37C for up to 4.5 h. Platelet aggregation and thromboxane generation were measured. Inhibition of platelet aggregation and thromboxane formation by 10 uM aspirin was maximal by 90 min. There was progressive inhibition by 3 uM aspirin during incubation for 270 min. By the end of this time there was also significant inhibition by 1 uM aspirin.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:36:50 GMT 2025` Edited by `admin` on `Mon Mar 31 18:36:50 GMT 2025`
Record UNII	JKW59XM343
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

EDAN	Locators: WHO-DD Sources:

Preferred Name

English

Aspirin Trelamine

Official Name

English

2-(Diethylamino)ethyl 2-acetoxybenzoate

Systematic Name

English

X-0023

Code

English

2-(ACETYLOXY)BENZOIC ACID 2-(DIETHYLAMINO)ETHYL ESTER

Systematic Name

English

ASPIRIN TRELAMINE [USAN]

Common Name

English

Benzoic acid, 2-(acetyloxy)-, 2-(diethylamino)ethyl ester

Systematic Name

English

Edan [WHO-DD]

Common Name

English

TF-0023

Code

English

SALICYLIC ACID, 2-(DIETHYLAMINO)ETHYL ESTER, ACETATE

Systematic Name

English

Code System Code Type Description

SMS_ID

300000040210